Oral Wegovy is a daily GLP-1 medication that supports weight loss by reducing appetite, slowing digestion, and helping you feel fuller for longer.

Unlike injections, it’s taken as a once-daily tablet, and doses are increased gradually over time to help your body adjust.

Below is what to expect week by week, including the standard dosing schedule.

Before you start: the routine matters

Oral Wegovy must be taken in a very specific way to ensure proper absorption:

• First thing in the morning
• On an empty stomach
• With a small amount of plain water only
• At least 30 minutes before food, drink, or other medication

Because oral semaglutide is absorbed through the stomach lining, food can significantly reduce effectiveness.

Most people find this routine becomes second nature within the first week.

The details provided here reflect common patient feedback regarding oral semaglutide. Please remember that individual responses vary; the specific timing and strength of these effects differ for everyone, and some may experience no shifts at all.

Weeks 1–4: Starting dose 

Dose: 1.5 mg once daily

This is the introductory dose and is designed to help your body adapt rather than deliver full weight loss effects.

You may notice:

• Mild appetite reduction
• Feeling full slightly sooner
• Subtle changes in food interest or cravings
• Possible mild nausea or digestive adjustment

Weight loss at this stage is usually minimal, and that’s completely expected.

Weeks 5–8: Early increase phase

Dose: 4 mg once daily

At this stage, appetite changes typically become more noticeable.

Common experiences include:

• Reduced hunger between meals
• Smaller portions feeling satisfying
• Fewer snack cravings
• Temporary return of mild side effects during dose increase

This is often when people first notice a real shift in eating behaviour.

Weeks 9–12: Stronger appetite control

Dose: 9 mg once daily

This phase often brings more consistent effects.

You may notice:

• Stronger appetite suppression
• Less interest in high-calorie or habitual snacking
• More predictable eating patterns
• Gradual, steady weight loss

For many people, this is where results start to become more visible week to week.

Week 13 onwards: Maintenance phase

Dose: 25 mg once daily (maintenance dose)

This is the full therapeutic dose for long-term use.

At this stage, effects tend to stabilise:

• Appetite regulation feels more consistent
• Reduced “food noise” and cravings
• Continued gradual weight loss or maintenance
• Fewer side effects for most people

This is where the medication is working at its full intended strength.

Managing potential side effects

Like other GLP-1 treatments, you might experience digestive adjustments, which are most common when transitioning to a higher dose.

What results can you expect?

Research regarding oral semaglutide for obesity management indicates significant weight reduction when paired with habit changes. During the OASIS 4 clinical trial—the primary study supporting the MHRA’s decision to approve the 25 mg daily pill—participants achieved an average weight loss of 13.6% over a 64-week period, compared to just 2.2% in the control group. Ultimately, specific outcomes depend on how closely the routine is followed, the gradual dose increase, and each person’s metabolic response.

Results vary based on:

• Consistency in taking the medication
• Dose progression
• Diet and activity habits
• Individual metabolism and response